FDA 483 - Recipharm Monts - October 18, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Recipharm Monts, a sterile drug manufacturer in Monts, France, revealed significant deficiencies in its operations. The firm failed to establish and follow adequate procedures to prevent microbiological contamination, lacked proper validation of aseptic and sterilization processes, and exhibited poor cleaning techniques. Additionally, issues were identified in quality control unit responsibilities, data integrity, environmental monitoring, and the stability testing program.
ID · a83c3605-dbd3-4083-aab4-aa70216b587a